HackerNews中文版

GLP-1药物的第一阶效应显而易见：人们减轻了体重，诺和诺德和礼来赚得盆满钵满。但如果在十年内，10-15%的成年人都在使用减肥药，会发生什么？下游的后果讨论得较少，几乎肯定没有被纳入任何定价中。 2018年，美国联合航空公司为其机上杂志更换了更轻的纸张。每本减少一盎司。在4500个每日航班中，这每年节省了17万加仑的燃料。航空公司在这个层面上考虑重量，因为燃料是它们最大的可变成本。使用赛美特肽（semaglutide）的人平均减重约35磅。如果在典型的737航班上，12%的乘客正在使用这种药物，那么每个航班大约减少750磅的重量，相当于减少了12000本杂志的重量。联合航空花了几个月的时间来优化纸张，以每年节省29万美元的燃料。GLP-1在飞行人群中的普及可能会悄然为他们节省数量级更多的费用，而当乘客变轻时，票价并不会下降。食品供应链的影响更为明显，但规模更大。如果大部分人群的食量减少20-30%，对卡路里的需求就会下降。这不是偏好向沙拉转变，而是药理学上减少人们的食量。食品行业以前曾应对过口味变化，但从未面临过来自医疗系统的需求冲击。健康保险面临一个更微妙的问题。GLP-1覆盖的宣传是，这些药物可以预防后续昂贵的疾病：糖尿病、心脏病、关节置换。这可能是事实。但在美国分散的保险市场中，今天为药物支付费用的公司，可能并不是五年或十年后为该患者提供保险的公司。节省的费用落在了其他公司的资产负债表上。这种不匹配可能会单独拖慢采用的速度。肥胖与较低的劳动力参与率和较高的缺勤率相关。如果GLP-1显著降低肥胖率，整体劳动供给将会上升。更多的人在工作，健康相关的缺勤减少。这是一种宏观经济刺激，尽管没有人以这种方式来框架它，因为它来自制药公司，而不是国会。早期数据显示，GLP-1也减少了对酒精、尼古丁和赌博的渴望。针对阿片类药物使用障碍的第二阶段试验正在进行中。一种减肥药意外影响了帝亚吉欧的收入和赌场客流，这并不是任何人对Ozempic的原始投资理论中的内容。我认为最难以思考的影响是心理层面的。几个世纪以来，体重与羞耻、身份和社会等级交织在一起。当体重成为你通过处方管理的事情时，身体积极性、吸引力的社会动态、围绕饮食和自律的整个文化机制会发生什么？我没有一个好的框架来理解这一点。之前没有发生过类似的事情。市场将其视为制药故事。制药公司将捕捉到创造和破坏的总价值的一部分。其余的则在食品、航空公司、保险、劳动市场和社会行为之间重新分配。没有人的模型可能会同时覆盖所有这些。

查看原文

The first-order effects of GLP-1 drugs are obvious: people lose weight, Novo Nordisk and Eli Lilly print money. But what happens when 10-15% of the adult population is on weight-loss medication within a decade? The downstream consequences are less discussed and almost certainly not priced into anything.In 2018, United Airlines switched to lighter paper for its inflight magazine. One ounce per copy. Across 4,500 daily flights, that saved 170,000 gallons of fuel a year [1]. Airlines think about weight at this level of granularity because fuel is their single largest variable cost.Average weight loss on semaglutide is around 35 pounds per person. If 12% of passengers on a typical 737 have been on the drug, that's roughly 750 fewer pounds per flight, the equivalent of shaving the weight off 12,000 magazines. United spent months optimizing paper stock to save $290,000 a year in fuel. GLP-1 adoption across the flying population could quietly save them an order of magnitude more, and ticket prices don't adjust down when passengers get lighter.The food supply chain is more obvious but larger in scale. If a big share of the population eats 20-30% less, demand for calories drops. Not a shift in preferences toward salads. A pharmacological reduction in how much people eat, period. The food industry has dealt with changing tastes before. It has never faced a demand shock from the medical system.Health insurance has a subtler problem. The pitch for GLP-1 coverage is that the drugs prevent expensive conditions downstream: diabetes, heart disease, joint replacements. Probably true. But in America's fragmented insurance market, the company paying for the drug today probably isn't the one insuring that patient in five or ten years. The savings land on someone else's balance sheet. That mismatch could slow adoption by years on its own.Obesity correlates with lower workforce participation and higher absenteeism. If GLP-1s meaningfully reduce obesity rates, aggregate labor supply goes up. More people working, fewer health-related absences. That's a macroeconomic stimulus, except nobody frames it that way because it comes from a pharmaceutical company rather than from Congress.Early data suggests GLP-1s reduce cravings for alcohol, nicotine, and gambling too. Phase 2 trials for opioid use disorder are underway. A weight-loss drug that accidentally dents Diageo's revenue and casino foot traffic was not in anybody's original investment thesis for Ozempic.The effect I find hardest to think about is the psychological one. Weight has been tangled up with shame, identity, and social hierarchy for centuries. What happens to body positivity, the social dynamics of attractiveness, the entire cultural machinery around diet and discipline when weight becomes something you manage with a prescription? I don't have a good framework for it. Nothing comparable has happened before.The market is treating this as a pharma story. The drug companies will capture a fraction of the total value created and destroyed. The rest redistributes across food, airlines, insurance, labor markets, and social behavior. Nobody's model probably covers all of that at once.[1] https://www.cbsnews.com/news/united-hemispheres-magazine-print-edition/EDIT: Formatting

GLP-1的二级效应